Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method

• Published in: Antimicrobial agents and chemotherapy Vol. 59; no. 1; pp. 666 - 668
• Main Authors: Espinel-Ingroff, A, Chowdhary, A, Gonzalez, G M, Guinea, J, Hagen, F, Meis, J F, Thompson, 3rd, G R, Turnidge, J
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01-01-2015
• Subjects: Antifungal Agents; Antifungal Agents - pharmacology; Antifungal Agents - therapeutic use; Cryptococcosis - drug therapy; Cryptococcus gattii; Cryptococcus gattii - drug effects; Cryptococcus gattii - genetics; Cryptococcus neoformans; Cryptococcus neoformans - drug effects; Cryptococcus neoformans - genetics; Genotype; Humans; Microbial Sensitivity Tests; Nitriles; Nitriles - pharmacology; Nitriles - therapeutic use; Pyridines; Pyridines - pharmacology; Pyridines - therapeutic use; Susceptibility; Triazoles; Triazoles - pharmacology; Triazoles - therapeutic use
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.04055-14

Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and 406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25 μg/ml, respectively. These ECVs may aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.